broxuridine

Small moleculeexperimental

Bromodeoxyuridine is a synthetic nucleoside analogue with a chemical structure similar to thymidine. BrdU is commonly used to study cell proliferation in living tissues and has been studied as a radiosensitizer and diagnostic tool in people with cancer. — Wikipedia

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 1998 (NCT00003405)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • DNAINHIBITOR

    DNA inhibitor

Chemistry & pharmacology

Loading structure…

SMILES

O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br
Mol. weight
307.1 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5-bromodeoxyuridine
  • bromodeoxyuridine
  • bromodeoxyuridine
  • bromodeoxyuridine
  • bromodeoxyuridine
  • broxuridine
  • broxuridine
  • broxuridine
  • broxuridine
  • broxuridine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00003832Phase 2Jul 1, 1999National Cancer Institute (NCI), University of Colorado, Denver
NCT00003405Phase 2Apr 1, 1998National Cancer Institute (NCI), Rush University
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government2111998
Rush UniversityAcademic/Hospital1111998
University of Colorado, DenverAcademic/Hospital1011999
3 organizations
Page 1 / 1